Organon & Co独立审查:未发现往年从供应商处采购生物类似药时机存在不当行为的证据

美股速递
Feb 20

一项针对Organon & Co的独立审查结果显示,调查方未找到任何证据,能够证明该公司在往年从供应商处采购生物类似药的时机选择上存在不当行为。此次审查旨在澄清相关采购操作的时间点是否合规,最终结论表明,未发现存在问题的依据。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10